FIGURE 6.

Reduced CD68 cell recruitment in G2019S-LRRK2 rats treated with PF-06447475. 10- to 12-week-old male G2019S-LRRK2 BAC transgenic rats and G2019S− controls were unilaterally injected with 6 × 10⁹ rAAV2 α-synuclein viral particles and treated with 30 mg·kg⁻¹ b.i.d. by oral gavage with either PF-06447475 (PF-475) or control compound for 4 weeks. At least four rats were analyzed per experimental group by analysis of serial sections across the ipsilateral SNpc. A and B, representative coronal sections DAB-stained for CD68 with Nissl counterstain in G2019S+ (A) or G2019S− rats (B). C, stereological counts of CD68-positive cells across the ipsilateral midbrain in G0219S+ and G2019S− rats treated with control or PF-0644747 compounds. CD68 counts were always below 100 across the contralateral SNpc and did not vary between groups. Scale bars = 0.5 mm. *, p < 0.05; **, p < 0.01; n.s., p > 0.05, as calculated with one-way analysis of variance with Tukey's post hoc comparison. Data are mean ± S.E.